ABSTRACT
The placenta serves in immunological defense of the fetus, providing proteins essential for innate immunity. Maternal and fetal portions of two mammalian placenta types, discoid, and cotyledonary, were separated and analyzed for antibacterial activity using a culture-independent method. Antibacterial activity was detected in both maternal and fetal portions of all placenta types tested. Protease resistance and increased activity after boiling suggests that the factor is activated upon release from a larger molecule. Identification of this factor and the mechanism of activation will lead to a better understanding of the innate immune function provided by the placenta.
ABSTRACT
Screening for cognitive impairment following ICU discharge is recommended but not part of routine care. We sought to understand older adults' perspectives on screening for cognitive impairment following an ICU admission to inform the design and delivery of a cognitive screening intervention. DESIGN: Qualitative study using semi-structured interviews. SUBJECTS: Adults 60 years and older within 3 months of discharge from an ICU in an academic health system. INTERVENTIONS: Interviews were conducted via telephone, audio recorded and transcribed verbatim. All transcripts were coded in duplicate. Discrepancies were resolved by consensus. Codes were organized into themes and subthemes inductively. MEASUREMENTS AND MAIN RESULTS: We completed 22 interviews. The mean age of participants was 71 ± 6 years, 14 (63.6%) were men, 16 (72.7%) were White, and 6 (27.3%) were Black. Thematic analysis was organized around four themes: 1) receptivity to screening, 2) communication preferences, 3) information needs, and 4) provider involvement. Most participants were receptive to cognitive screening; this was influenced by trust in their providers and prior experience with cognitive screening and impairment. Participants preferred simple, direct, compassionate communication. They wanted to understand the screening procedure, the rationale for screening, and expectations for recovery. Participants desired input from their primary care provider to have their cognitive screening results placed in the context of their overall health, because they had a trusted relationship, and for convenience. CONCLUSIONS: Participants demonstrated limited understanding of and exposure to cognitive screening but see it as potentially beneficial following an ICU stay. Providers should use simple, straightforward language and place emphasis on expectations. Resources may be needed to assist primary care providers with capacity to provide cognitive screening and interpret results for ICU survivors. Implementation strategies can include educational materials for clinicians and patients on rationale for screening and recovery expectations.
ABSTRACT
BACKGROUND: Mycobacterium leprae is an acid fast bacterium that causes leprosy, also known as Hansen's disease. M. leprae spreads primarily through respiratory droplets and skin contact, and widespread migration of the human population may lead to infection in non-endemic areas. Leprosy mainly affects the skin, peripheral nerves, mucosa of the upper respiratory tract, and the eyes, presenting as a spectrum of disease based on the host immune response consisting of skin lesions, areas of anesthesia, local tissue destruction, and even blindness or glomerulonephritis in severe cases. CASE DESCRIPTION: We describe a case of leprosy presenting in a South Dakota resident. Before this case, leprosy had not been reported in South Dakota in 11 years. The patient presented with chronic skin lesions with areas of anesthesia on her right knee and left elbow. Physical exam was unremarkable aside from the skin lesions, which had areas of decreased sensation over the involved skin. Biopsy of the lesions was positive for noncaseating granulomas with lymphocytic infiltrate that were acid-fast bacillus positive. The biopsy was sent to the National Hansen's Disease Program for further molecular testing, which confirmed M. leprae infection. The patient underwent 12 months of dapsone 100 mg po qd and rifampin 600 mg po qd per U.S. guidelines from the National Hansen's Disease Program Clinical Center. The patient responded well to treatment until developing a reversal reaction after nine months, which was resolved with corticosteroid treatment. Both dermatology and infectious disease continue to follow the patient, and she continues to do well with no evidence of recurrence of active infection or evidence of reversal reaction. CONCLUSIONS: It is important that clinicians be aware of the possibility of uncommon presentations/diseases such as leprosy in areas where it is extremely rare (such as South Dakota) due to immigration and travel among patients. The rarity of leprosy in areas like South Dakota, in addition to its potential for misdiagnosis, may lead to delay of treatment in the patient. Delays in treatment can allow progression of the disease causing skin lesions and possible nerve damage.
